| Shane Thomas Bealer, DO | |
|
1 Mellon Way, Latrobe, PA 15650-1197 | |
| (724) 537-1207 | |
| Not Available |
| Full Name | Shane Thomas Bealer |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 1 Mellon Way, Latrobe, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154941409 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OT019811 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shane Thomas Bealer, DO 10 Honey Locust Rd, Levittown, PA 19056-1125 Ph: (267) 984-1162 | Shane Thomas Bealer, DO 1 Mellon Way, Latrobe, PA 15650-1197 Ph: (724) 537-1207 |
News Archive
The weight loss pill Qnexa has been once rejected by the FDA over safety concerns. But this Wednesday it will get a second chance before an FDA advisory committee. Qnexa maker Vivus Inc. hopes something might come out of this second chance. The company will be submitting new safety data from patients who took Qnexa for a second year after completing a one-year clinical trial.
The National Association of Pharmacy Regulatory Authorities (NAPRA) has issued a directive to the provinces requesting that pharmacists not sell Natural Health Products (NHPs) without a Drug Identification Number (DIN), Natural Product Number (NPN) or Drug Identification Number for Homeopathic Medicine (DIN-HM). NAPRA did not engage in consultations with industry participants who will be adversely affected by this move.
In the three months since Johnson & Johnson's COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention.
Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.
› Verified 3 days ago
Luke Egan, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Mellon Way, Latrobe, PA 15650 Phone: 724-537-1207 | |
Dr. Christopher C. Drescher, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Mellon Way, Latrobe, PA 15650 Phone: 724-537-1207 | |
Karren Vlahos, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 121 W 2nd Ave, Latrobe, PA 15650 Phone: 724-537-1207 | |
Emily Katherine Fellin, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Mellon Way, Latrobe Family Medicine Residency Program, Latrobe, PA 15650 Phone: 724-537-1485 | |
Dr. Francis E Meyers, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 555 Route 217, Suite 5, Latrobe, PA 15650 Phone: 724-694-0274 Fax: 724-694-0383 | |
Dr. Anna Nash Gorman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Mellon Way, Latrobe, PA 15650 Phone: 724-537-1207 | |
Teresa Beth Malec, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Mellon Way, Latrobe Family Medicine Residency Program, Latrobe, PA 15650 Phone: 724-537-1485 |